Effects of topical bimatoprost 0.01% and timolol 0.5% on circadian IOP, blood pressure and perfusion pressure in patients with glaucoma or ocular hypertension : a randomized, double masked, placebo-controlled clinical trial by F. Oddone et al.
RESEARCH ARTICLE
Effects of Topical Bimatoprost 0.01% and
Timolol 0.5% on Circadian IOP, Blood
Pressure and Perfusion Pressure in Patients
with Glaucoma or Ocular Hypertension: A
Randomized, Double Masked, Placebo-
Controlled Clinical Trial
Francesco Oddone1☯*, Luca Rossetti2☯, Lucia Tanga1‡, Francesca Berardo1‡,
Manuela Ferrazza1‡, Manuele Michelessi1‡, Gloria Roberti1‡, Gianluca Manni3☯,
Marco Centofanti1,3†
1 Clinical and Research Institute of Ophthalmology IRCCS Fondazione G. B. Bietti, Via Livenza 3, 00198,
Rome, Italy, 2 Clinica Oculistica, Dipartimento di Scienze della Salute, University of Milan, San Paolo
Hospital, Via Antonio di Rudinì, 8 20142, Milan, Italy, 3 Clinical Science and Translational Medicine
Department, University of Rome Tor Vergata, Viale Oxford 81, 00133, Rome, Italy
†Deceased.
☯ These authors contributed equally to this work.
‡ These authors also contributed equally to this work.
* oddonef@gmail.com
Abstract
Purpose
To compare the 24-hour (24h) effects on intraocular pressure (IOP) and cardiovascular
parameters of timolol 0.5% and bimatoprost 0.01% in open angle glaucoma and ocular
hypertensive subjects.
Methods
In this prospective, randomized, double masked, crossover, clinical trial, after washout from
previous medications enrolled subjects underwent 24h IOP, blood pressure (BP) and heart
rate (HR) measurements and were randomized to either topical bimatoprost 0.01% at night
plus placebo in the morning or to timolol 0.5% bid. After 8 weeks of treatment a second 24h
assessment of IOP, BP and HR was performed and then subjects switched to the opposite
treatment for additional 8 weeks when a third 24h assessment was performed. The primary
endpoint was the comparison of the mean 24h IOP after each treatment. Secondary end-
points included the comparisons of IOP at each timepoint of the 24h curve and the compari-
son of BP, HR, ocular perfusion pressure and tolerability.
Results
Mean untreated 24h IOP was 20.3 mmHg (95%CI 19.0 to 21.6). Mean 24h IOP was signifi-
cantly lower after 8 weeks of treatment with bimatoprost 0.01% than after 8 weeks of
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treatment with timolol 0.5% bid (15.7 vs 16.8 mmHg, p = 0.0003). Mean IOP during the day
hours was significantly reduced from baseline by both drugs while mean IOP during the
night hours was reduced by -2.3 mmHg (p = 0.0002) by bimatoprost 0.01% plus placebo
and by -1.1 mmHg by timolol 0.5% bid (p = 0.06). Timolol 0.5% significantly reduced the
mean 24h systolic BP from baseline, the diastolic BP during the day hours, the HR during
the night hours, and the mean 24h systolic ocular perfusion pressure.
Conclusion
Both Bimatoprost 0.01% and Timolol 0.5% are effective in reducing the mean 24h IOP from
an untreated baseline but Bimatoprost 0.01% is more effective than timolol 0.5% throughout
the 24h. Timolol 0.5% effect on IOP is reduced during the night hours and is associated with
reduced BP, HR and ocular perfusion pressure.
Trial Registration
EU Clinical Trial Register and EudraCT# 2010-024272-26
Introduction
Lowering intraocular pressure (IOP) is the only evidence based method available to treat glau-
coma and it has been shown in large randomized clinical trials that each mmHg of IOP reduc-
tion is associated with a reduction of the risk of visual field damage progression [1–4].
Medical therapy is widely accepted as the first step in the management of glaucoma and
among the pharmacological agents available prostaglandin and prostamide analogues and
beta-blockers are widely used as first line drugs for their IOP lowering efficacy and overall
safety profile.
Nevertheless differences do exist between these agents in terms of IOP lowering effect and
safety profiles and cost-effectiveness [5], and the knowledge of these differences is important
for individualizing the treatment strategy for the single glaucoma patient.
Among topical beta-blockers Timolol maleate is the most widely used and its efficacy and
safety have been thoroughly studied since its first introduction in the medical therapy of glau-
coma in the late 70s. Timolol 0.5% is able to reduce the IOP on average by 20–25% [6] with 2
daily administrations 12 hours apart. Its topical tolerability profile is very good while issues
arise when considering the systemic safety. In fact timolol is contra-indicated in individuals
suffering by sinus bradycardia, heart block or cardiac failure and chronic obstructive pulmo-
nary disease. Moreover the use of beta-blockers in patients with glaucoma has been reported to
be associated with the reduction of blood pressure (BP) and heart rate (HR) [7,8].
Bimatoprost, a prostamide analogue, has been shown to be effective in lowering the IOP by
30–35% at the concentration of 0.03% [9,10] and to be associated with local adverse effects
including conjunctival hyperemia, eyelash growth and skin pigmentation. Recently, a new for-
mulation of bimatoprost with a reduced concentration of the active drug (0.01%) has been
made available for treating glaucoma, and it showed a similar ocular hypotensive efficacy com-
pared to the 0.03% formulation and an improved local tolerability profile [11].
It has been shown by several studies that the IOP in healthy individuals undergo physiologi-
cal diurnal and nocturnal variations with peaks and troughs that can vary according to the pop-
ulation being studied or to the methodology of IOP measurement being used. These variations
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have been found more pronounced in untreated patients with glaucoma and are subject to
modifications induced by the topical hypotensive therapy [12]. Similarly also the blood pres-
sure varies physiologically in the 24h and its variations may be influenced by systemic and topi-
cal therapies.
Despite several reports have been published about the efficacy and safety of topical timolol
and bimatoprost in comparison with other drugs, only one single-masked parallel study com-
pared the 24h effect of timolol 0.5% and bimatoprost 0.03% on IOP and no 24h direct compari-
sons are available involving bimatoprost 0.01%. [13] Moreover little information is available
coming from direct comparisons regarding the effects of these pharmacological agents on car-
diovascular parameters in the 24h.
The purpose of the present study is to directly compare the 24 hour ocular hypotensive effi-
cacy and cardiovascular effects of bimatoprost 0.01% with those of timolol 0.5% in open angle
glaucoma and ocular hypertensive subjects naïve to treatment or washed-out from previous
topical medications.
Methods
This prospective, randomized, double-masked, cross-over clinical trial (registered with
EudraCT # 2010-024272-26, https://eudract.ema.europa.eu, and available in the EU Clinical
Trials Register, https://www.clinicaltrialsregister.eu) was carried out between February 2011
and January 2012 at the Glaucoma Unit of the IRCCS Fondazione G.B.Bietti, Rome (Italy) and
the authors confirm that all ongoing and related trials for this drugs are registered. Newly diag-
nosed or previously treated glaucoma or ocular hypertensive patients after adequate washout
were enrolled. The study protocol was approved by the IRCCS Fondazione G.B.Bietti Ethical
Committee named "ASL Roma A” and was in accordance with the principles of the declaration
of Helsinki and all patients signed a written informed consent before enrollment.
Inclusion criteria were a diagnosis of primary open angle glaucoma or ocular hypertension
based on the 4th edition of the European Glaucoma Society Guidelines criteria, an IOP<27
mmHg for untreated newly diagnosed patients or IOP<22 mmHg for patients on treatment
with any hypotensive medication in monotherapy and<27 mmHg after adequate washout
(see below). The cut-off point of 27 mmHg was introduced as a safety criterium for glaucoma
patients in order to maximise the likelyhood of having IOPs on treatment below 21 mmHg
assuming a minimum hypotensive efficacy of the study drugs of 25% from untreated baseline
IOP values. Washout IOP had to be>21 mmHg for ocular hypertension subjects while no
lower limit of untreated IOP was set for glaucoma patients.
Exclusion criteria were defined as age< 18 years, any past or active ocular disease other
than glaucoma, closed/barely open anterior chamber angle or history of acute angle closure,
any cause of secondary elevation of IOP, argon or selective laser trabeculoplasty within the last
six months, any previous ocular surgery, ocular inflammation/infection occurred within three
months prior to the pre-trial visit, uncontrolled systemic diseases that might require initiating
or altering concomitant use of systemic medications that can interfere with the study drugs or
with IOP (e.g. beta-adrenergic antagonists, alpha-adrenergic agonists, calcium channel block-
ers, ACE inhibitors and angiotensin II receptor antagonists), hypersensitivity to benzalkonium
chloride or to any other component of the trial drug solutions, contraindications to the study
drugs including reactive airway disease, chronic obstructive pulmonary disease, sinus bradycar-
dia, second or third degree atrioventricular block, overt cardiac failure, or cardiogenic shock,
severe allergic rhinitis and bronchial hyperreactivity, pregnancy, nursing or childbearing
potential without using adequate contraception.
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Study plan and randomization
Treatment naive patients and previously treated patients after adequate washout from previous
medications and who fulfilled the eligibility requirements detailed above were included in this
study.
Washout time varied according to the ongoing treatment and was 6 weeks for prostaglan-
din/prostamide analogues, 4 weeks for beta-blockers and alpha-agonists, 2 weeks for carbonic
anhydrase inhibitors and miotics [6].
At baseline enrolled patients were admitted and performed a 24h IOP, BP and HR curve
and were then randomized, according to a 1:1 computer-generated randomization code list, to
be treated with either bimatoprost 0.01% administered once at night (08.00pm) + placebo
administered once in the morning (at 8.00am) or timolol 0.5% administered twice daily
(8.00am and 8.00pm). After 8 weeks of the first treatment a second 24h IOP, BP, and HR curve
was performed and then patients were crossed-over to the opposite treatment regimen
(patients on bimatoprost 0.01% + placebo switched to timolol 0.5% twice daily and vice versa)
and were treated for 8 additional weeks. At the end of the follow-up (16 weeks from baseline
and 8 weeks after the cross-over) a third 24h IOP, BP and HR assessment was performed.
Despite there was no washout between the two treatment phases in the crossover design, the
treatment duration in each phase was 8 weeks and allowed to remove the potential effect of the
previous treatment (either timolol 0.5% or bimatoprost 0.01%) on the IOP of the second phase.
This is based on the knowledge of the washout time for the study drugs which is known to be 4
weeks for timolol and 4–6 weeks for bimatoprost [6].
At baseline, week 8 and week 16, patients were admitted and IOP was measured by applana-
tion tonometry at 6 time points over the 24h (in the sitting position by Goldmann applanation
tonometry at 8:00, 12:00, 16:00 and 20:00 o’clock, and in the supine position by Perkins appla-
nation tonometry at 00:00 and 04:00 o’clock). Two additional safety visits were performed at
week 4 and 12 and during these visits IOP was measured in the sitting position by Goldmann
applanation tonometry at 12.00 o’clock.
The mean of two readings or the median of three readings in case of differences>2 mmHg
was reported for the analysis and the same calibrated Goldmann applanation tonometer was
used by the same trained investigator in each center throughout the study.
At baseline visit patients’ ophthalmic and systemic history was recorded and gonioscopy,
pachymetry, and standard automated acromatic perimetry, using the Humphrey 24–2 SITA
Standard program, were performed. In addition to the IOP measurements a complete ophthal-
mological evaluation was performed at baseline and at each follow-up visits including best cor-
rected visual acuity measurement, slit lamp examination, ophthalmoscopy and adverse events
recording. At baseline and at week 8 and 16 systolic and diastolic BP and HR have been mea-
sured at each of the 6 time points of the 24h curve before the IOP measurements by the same
trained investigator. Heart rate was measured manually at the radial artery by counting number
of beats in 1 minute and blood pressure was measured manually by sphygmomanometry and it
was reported as the mean value of three repeated measurement taken at each timepoint.
Additionally patients were asked to give specific answers to the following 3 questions at
each follow-up visits: 1) did you notice any redness in your eyes since last visit? 2) did you
experience any dry eye or foreign body sensation since last visit? 3) did you experience any eye
burning sensation since last visit?
Study medications
Two masked sets of study medications have been prepared, one set containing bimatoprost
0.01% for the evening administration and placebo for the morning administration and one set
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containing two bottles of timolol 0.5%, one for the morning and one for the evening adminis-
tration. Masking, randomization list generation, labelling, blinding, packaging, and shipping of
trial medications was handled by Pierrel Research IMP s.r.l..
At baseline, after randomization, 1 masked box containing 3 sets of study medications cor-
responding to treatment-phase 1 was dispensed to each randomized patient. At the week 8 visit
the medications were collected from the patients and a second box containing 3 sets of study
medications corresponding of treatment-phase 2 was dispensed to each patient.
During the admissions at baseline and at the week 8 and 16 visits the masked study drugs
were administered according to the schedule by the study investigators.
Study endpoints
The primary endpoint was the mean 24h IOP after 8 weeks of treatment and the primary com-
parison was the mean 24h IOP between the two active treatments. The secondary endpoints
were: the mean IOP, BP and HR at each of the 6 timepoints of the 24h curve, the mean day
(average of the 8:00, 12:00, 16:00 and 20:00 o’clock timepoints) and night (average of the 00:00
and 04:00 o’clock timepoints) IOP, BP and HR, the mean 24h diastolic and systolic ocular per-
fusion pressures (OPP, calculated as the difference between either the mean 24h systolic or the
mean 24h diastolic blood pressure and the mean 24h IOP) and the incidence of adverse events.
The secondary comparisons included the comparison between the active treatments and
between each treatment and the baseline of: the mean timepoint IOP, the mean day and mean
night IOP, the mean BP and HR, the mean diastolic and systolic OPP and the adverse events.
Additionally the mean 24h IOP following each treatment in the two arms of the crossover
design were compared between and within treatment phases.
The ocular perfusion pressure was calculated as the difference between either the mean 24h
systolic or the mean 24h diastolic blood pressure and the mean 24h IOP.
Statistical analysis
If only one eye was eligible as trial eye, that eye was included. If both eyes were eligible only the
eye with highest baseline mean 24h IOP was included in the statistical analysis.
Only patients completing the baseline, 8 weeks and 16 weeks visits (24h IOP assessment vis-
its) were included in the efficacy analysis. All randomized patients taking any amount of the
study medication were included in the safety analysis.
Data have been described as mean and 95% confidence interval (CI) for continuous vari-
ables and frequencies for categorical variables. IOP data have been analysed by treatment and
not by group, thus pooling data obtained from the same treatment irrespectively of the treat-
ment sequence. A mixed effect model with time and drug as fixed effects and patients as ran-
dom effect was used to test the null hypotesis that the mean 24h IOP between treatments is not
different. The treatment sequence (either first bimatoprost 0.01% + placebo or first timolol
0.5% twice daily) was included in the model as fixed effect to test the interaction between drug
and treatment sequence and to explore the presence of potential carry-over effects. Post-hoc
paired comparisons have been performed by paired t-test or Wilcoxon sign rank test after nor-
mality check performed by Shapiro-Wilk test.
Categorical variables such as proportions and safety variables have been analyzed using the
McNemar test. Statistical significance was set at the 5% level
We established a minimum sample of 29 participants based on the primary outcome
(the comparison of the mean 24h IOP after 8 weeks of treatment pooling data from the same
treatment in the crossover design) to have a 80% probability to detect a difference between
treatments at a two-sided 0.05 significance level if the true difference between treatments is
24-Hour Efficacy and Safety of Bimatoprost 0.01% and Timolol 0.5%
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1 mmHg. This is based on the assumption that the within-patient standard deviation of the
response variable is 2 mmHg.
Results
A total of 35 patients were enrolled in this study between May and August 2012 and 32 were
included in the efficacy and safety analysis (24 glaucomatous, 8 ocular hypertensive, mean age
61.0±11 years, 17 females and 15 males). Three patients were lost to follow-up after randomiza-
tion without performing any follow-up visit and were excluded from the analysis (Fig 1). All
enrolled patients had both eyes eligible for the study and received bilateral treatment but only
data from the eye with the highest IOP at baseline were considered for the analysis.
Mean 24h IOP at baseline was 20.3 mmHg (95%CI 19.0 to 21.6) and after 8 weeks of treat-
ment it was statistically significantly reduced by both treatments (15.7 mmHg, 95%CI 14.8 to
16.7, mean change from baseline -4.5 mmHg, 95%CI -3.6 to -5.4, p<0.0001 with bimatoprost
0.01% plus placebo; 16.8 mmHg, 95%CI 15.8 to 17.8, mean change from baseline -3.5 mmHg,
95%CI -2.6 to -4.4, with timolol 0.5% bid, p<0.0001).
Mean 24h IOP was statistically significantly lower after 8 weeks of treatment with bimato-
prost 0.01% plus placebo than after 8 weeks of treatment with timolol 0.5% bid (mean differ-
ence between drugs -1.04, 95%CI -0.35 to -1.72, p = 0.0003). The mixed effects model
confirmed that the mean 24h IOP changes from baseline were statistically significantly influ-
enced by type of topical drug (p = 0.0041) with no statistically significant interaction between
drug and treatment sequence (either first timolol 0.5% and second bimatoprost 0.01% or first
Fig 1. Study flow diagram.
doi:10.1371/journal.pone.0140601.g001
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bimatoprost0.01% and second timolol 0.5%) indicating no carry-over effects between drugs in
the cross-over design (p = 0.97).
The paired comparisons of the mean 24h IOP in each arm of the crossover design con-
firmed that the mean 24h IOP during timolol 0.5% treatment was not different when timolol
was used as first (16.5±2.5 mmHg) or as second drug (17.1±2.1 mmHg, p = 0.51) in the cross-
over design. Similarly the mean 24h IOP during bimatoprost 0.01% treatment was not different
when bimatoprost was used as first (15.8±2.2 mmHg) or as second drug (15.7±2.6 mmHg,
p = 0.9). Moreover the mean 24h IOP was statistically lower during bimatoprost 0.01% than
during timolol 0.5% in both study arms so either when bimatoprost 0.01% was used as first
drug (15.8±2.2 vs 17.1±2.1, p = 0.0008) and when it was used as second drug in the crossover
design (15.7±2.6 vs 16.5±2.5, p = 0.013). This data also confirm the absence of any carry-over
effects of the study drugs between the two study phases of the crossover design.
Mean day IOP (calculated as the mean of the IOP at the 8:00, 12:00, 16:00 and 20:00 o’clock
timepoints) was statistically significantly reduced compared to baseline by both bimatoprost
0.01% plus placebo (-5.4 mmHg, 95% CI -4.4 to -6.4, p<0.0001) and by timolol 0.5% bid
(-4.4 mmHg, 95% CI -3.5 to -5.3 p<0.0001).
Mean night IOP (calculated as the mean of the IOP at the 00:00 and 04:00 o’clock time-
points) was reduced by -2.3 mmHg (95%CI -1.2 to -3.4, p = 0.0002) compared to baseline by
bimatoprost 0.01% plus placebo and by -1.1 mmHg (95%CI 0.0 to -2.3, p = 0.06) by timolol
0.5% bid. Full details are reported in Table 1.
The mean IOP at all individual timepoints of the 24h curve after 8 weeks of treatment with
bimatoprost 0.01% plus placebo was significantly lower than the corresponding timepoints at
baseline (full details are given in Table 1). The mean IOP measured at the day timepoints of the
Table 1. Comparison of mean intraocular pressure (mmHg) at baseline and after treatment with bimatoprost 0.01% once at night and after timolol
0.5% bid.
Measurement Baseline Timolol
0.5% bid
Mean
difference from
baseline
p value Bimatoprost
0.01% plus
placebo
Mean
difference from
baseline
p value Mean difference
between
treatments
p
value
Mean
(95% CI)
Mean
(95% CI)
Mean (95% CI) - Mean (95% CI) Mean (95% CI) - Mean (95% CI) -
Mean 24h IOP 20.3 (19.0
to 21.6)
16.8 (15.8
to 17.8)
-3.5 (-2.6 to
-4.4)
<0.0001 15.7 (14.8 to 16.7) -4.5 (-3.6 to
-5.4)
<0.0001 -1.0 (-0.3 to -1.7) 0.0003
Mean Day
IOP
20.9 (19.6
to 22.3)
16.5 (15.5
to 17.5)
-4.4 (-3.5 to
-5.3)
<0.0001 15.5 (14.6 to 16.4) -5.4 (-4.4 to
-6.4)
<0.0001 -1.0 (-0.3 to -1.6) 0.0007
Mean Night
IOP
18.6 (17.2
to 20.0)
17.5 (16.1
to 18.8)
-1.1 (0.0 to -2.3) 0.056 16.3 (15.2 to 17.5) -2.3 (-1.2 to
-3.4)
0.0002 -1.1 (-0.2 to 2.1) 0.0019
8:00 22.5 (20.6
to 24.4)
17.5 (16.3
to 18.6)
-5.0 (-3.2 to
-6.8)
<0.0001 15.9 (14.9 to 16.9) -6.6 (-4.8 to
-8.3)
<0.0001 -1.5 (-0.5 to -2.5) 0.0014
12:00 20.8 (19.0
to 22.2)
16.2 (15.1
to 17.4)
-4.5 (-3.2 to
-5.9)
<0.0001 15.4 (14.3 to 16.5) -5.4 (-4.1 to
-6.8)
<0.0001 -0.9 (-0.1 to -1.7) 0.045
16:00 21.1 (19.5
to 22.8)
16.1 (14.9
to 17.4)
-5.0 (-3.9 to
-6.1)
<0.0001 14.9 (13.8 to 15.9) -6.3 (-4.8 to
-7.7)
<0.0001 -1.3 (-0.2 to -2.4) 0.03
20:00 19.3 (18.0
to 20.5)
16.0 (14.8
to 17.2)
-3.3 (-2.1 to
-4.5)
<0.0001 15.6 (14.4 to 16.8) -3.7 (-2.4 to
-4.9)
<0.0001 -0.4 (-0.7 to -1.6) 0.56
00:00 18.2 (16.8
to 19.5)
17.3 (15.9
to 18.7)
-0.9 (+0.6 to
-2.1)
0.23 16.1 (14.9 to 17.4) -2 (-0.65 to -3.4) 0.0034 -1.2 (-0.2 to -2.1) 0.0069
04:00 19.1 (17.3
to 20.8)
17.6 (16.2
to 19.1)
-1.4 (0.0 to -2.8) 0.092 16.6 (15.3 to 17.8) -2.5 (-1.0 to
-4.0)
0.0014 -1.0 (0.0 to -2.2) 0.012
IOP = Intraocular pressure; CI = conﬁdence interval; bid = bis in die. Mean day IOP = mean of 08:00, 1200, 16:00 and 20:00 o’clock timeponts; Mean
night IOP = mean of 00:00 and 04:00 o’clock timepoints.
doi:10.1371/journal.pone.0140601.t001
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24h curve (8:00, 12:00, 16:00, 20:00) after 8 weeks of treatment with timolol 0.5% bid was sig-
nificantly lower compared to the corresponding timepoints at baseline. The mean IOP at the
00.00 and 04.00 timepoints (night timepoints) were not statistically significantly lower than the
baseline values (full details in Table 1 and Fig 2).
After 8 weeks of treatment with timolol 0.5% bid systolic BP was significantly lower com-
pared to baseline at all but one (00.00 o’clock) timepoints of the 24h curve. After 8 weeks of
treatment with bimatoprost 0.01% systolic BP was not different from the baseline values at all
timepoints of the 24h curve (Fig 3A). After 8 weeks of treatment with timolol 0.5% bid diastolic
BP was significantly lower compared to baseline at the 8.00, 12:00 and 16:00 o’clock timepoints.
After 8 weeks of treatment with bimatoprost 0.01% diastolic BP was not different compared to
the baseline at all timepoints (Fig 3B). Heart rate was significantly lower compared to baseline
at 12:00, 16:00, 00:00 and 04:00 after timolol 0.5% bid treatment and was unchanged at all time-
points compared to baseline after bimatoprost 0.01% treatment (Fig 3C). The effects of the
2 treatment sequences on IOP, BP and HR are also displayed separately in Fig 4.
Mean 24h systolic OPP was 109.2±15.7 mmHg at baseline and was significantly lower after
8 weeks of treatment with timolol 0.5% bid (105.2±11.4, p = 0.024) while it was unchanged
compared to baseline after treatment with bimatoprost 0.01% (110.9±14.5 mmHg, p = 0.41).
Mean 24h systolic OPP was lower after 8 weeks treatment with timolol 0.5% bid than after
treatment with bimatoprost 0.01% plus placebo (105.2±11.4 vs 110.9±14.5 mmHg, mean dif-
ference -5.7 mmHg (95%CI -2.99/-8.4 mmHg), p = 0.0002).
Fig 2. Intraocular pressure at each time point of the daily curve. Error bars represents standard error; * = p<5% for timepoint comparison versus
baseline; § = p<5% for timepoint comparison between timolol 0.5% bid and bimatoprost 0.01% plus placebo.
doi:10.1371/journal.pone.0140601.g002
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Fig 3. Systolic (A) and diastolic (B) blood pressure and heart rate (C) at each timepoint of the 24h curve at baseline (continuous line), during
timolol 0.5% bid (dashed line) and during bimatoprost 0.01% plus placebo treatment (dotted line). Bpm = beats per minute. Error bars represents
standard error; * = p<5% for timepoint comparison versus baseline; § = p<5% for timepoint comparison between timolol 0.5% bid and bimatoprost 0.01%
plus placebo.
doi:10.1371/journal.pone.0140601.g003
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Mean 24h diastolic OPP was significantly higher than baseline after 8 weeks treatment with
bimatoprost 0.01% (63.1±9.1 mmHg vs 59.5±7.7 mmHg, p = 0.0013) while it was similar to the
baseline value after 8 weeks of treatment with timolol 0.5% bid (59.8±7.3 mmHg vs 59.5±7.7
mmHg, p = 0.72). The mean 24h diastolic OPP was higher after 8 weeks treatment with bima-
toprost 0.01% than after treatment with timolol 0.5% bid (63.1±9.1 vs 59.8±7.3 mmHg, men
difference 3.3 mmHg (95%CI 1.5/5.2 mmHg) p = 0.0009).
Concerning local tolerability burning was reported by 1 patient (3.1%) during timolol 0.5%
treatment and by 2 patients (6.2%, p = 1.0) during bimatoprost 0.01% treatment. Conjunctival
hyperemia was reported by 2 patients (6.2%) during timolol 0.5% treatment and by 2 patients
(6.2%, p = 1.0) during bimatoprost 0.01% treatment. One patient reported episodes of extra
systole during timolol 0.5% treatment and they were judged as not related with the study
drugs. No serious adverse events occurred during the study.
Discussion
In this study the 24h ocular hypotensive efficacy and the effects on BP and HR of bimatoprost
0.01% administered once at night were investigated and compared to those of timolol 0.5%
administered twice daily. According to our results both bimatoprost and timolol are effective
in reducing the mean 24h IOP in glaucomatous and ocular hypertensive subjects from an aver-
age untreated baseline IOP of 20.3 mmHg. Nevertheless the mean 24h IOP at the end of the
follow-up was found to be significantly lower with bimatoprost 0.01% than with timolol 0.5%.
Moreover According to our data, bimatoprost 0.01% and timolol 0.5% exerted different effects
on the 24h IOP profiles. In fact, when patients were treated with bimatoprost 0.01%, the IOP
was found to be significantly reduced at each individual time-point of the 24h curve compared
to the corresponding baseline untreated timepoint and this was true for both the day and for
the night time-points. Differently when patients were on timolol 0.5% IOP was found to be
lower than baseline at all day time-points (08:00, 12:00, 16:00, 20:00 o’clock) but not at 00.00
and 04:00 o’clock (night timepoints). This finding is in agreement with previous works by
Fig 4. Display of the mean 24 hour IOP (A), systolic BP (B), diastolic BP (C) and heart rate (D) of the
two arms of the study at baseline, at 8 weeks before the crossover and at 16 weeks after the
crossover. The dotted line indicates the study arm that received bimatoprost 0.01% plus placebo as first
treatment and timolol 0.5% bid as second treatment. The continous line indicates the study arm that received
timolol 0.5% bid as first treatment and bimatoprost 0.01% plus placebo as second treatment.
IOP = intraocular pressure, BP = blood pressure.
doi:10.1371/journal.pone.0140601.g004
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Orzalesi et al. [14] who compared the 24h IOP reduction induced by timolol 0.5% and the
hypotensive lipid latanoprost 0.005%, in glaucoma or ocular hypertension patients and found
that while latanoprost seemed to lead to a fairly uniform circadian reduction in IOP timolol
seemed to be less effective during the nighttime hours. Our results are also in agreement with
those by Quaranta et al. [15] who found that timolol induced a greater reduction in IOP during
the day (8 AM to 8 PM) and a less reduction during the night and are in accordance also with
Konstas et al. [16].
Liu and co-authors [17] investigated the nocturnal effects of once-daily timolol and latano-
prost on IOP in patients with ocular hypertension or glaucoma and found that in the nocturnal
period, IOP with timolol treatment was not different from the IOP with no medication and
was significantly higher than IOP with the latanoprost treatment.
More recently the same group published the results of a prospective, open-label experimen-
tal 24h investigation of the effects of bimatoprost 0.01% monotherapy on IOP and ocular per-
fusion pressure and reported that the diurnal and nocturnal IOP was significantly lower, and
the ocular perfusion pressure was significantly higher, with bimatoprost 0.01% treatment com-
pared to an untreated baseline [18].
Our findings are likely to be related to different effects on acqueus humor dynamics exerted
by bimatoprost and timolol over the 24h as recently reported by Gulati and co-workers who
explored the aqueous humor dynamics in a cross-over, randomized, double masked clinical
study in patients treated with different ocular hypotensive medications. The authors found that
during the night-time aqueous inflow is physiologically reduced in untreated eyes by 47% and
that topical treatment with timolol 0.5% is substantially ineffective in further reducing the
inflow during the night hours with consequent weak effect on IOP [19]. Interestingly in the
same study it was found that prostaglandin analogues (latanoprost) significantly reduced the
IOP during both day and night but the reduction at night was less than the reduction obtained
during the day and this finding was associated with a reduced effect on uveoscleral outflow
during the night hours. This finding is in agreement with the behaviour of IOP observed in the
present study with bimatoprost 0.01% which was associated with a significant reduction of IOP
throughout the 24 hours that appeared less pronounced during the night hours.
Our results are not in agreement with the results of a systematic review and meta-analysis
by Lee and co-workers [20]. The authors evaluated the night-time IOP and BP response to
timolol treatment in patients with ocular hypertension or primary open-angle glaucoma from
9 previously published articles involving overall 340 patients. The results suggest that topical
timolol therapy provides an ocular hypotensive effect over the 24-hour curve, including the
nighttime hours, with small reductions in the systolic and diastolic pressures and no alterations
of the ocular perfusion pressure over 24 hours. The disagreement with the results of the present
study could be due to several factors mainly related to differences in the sample populations
and in the study methodology. In fact in our study IOP was measured in the supine position at
the night time-points while in 8 out of the 9 articles included in the meta-analysis the night
IOP was measured only in the sitting position.
In addition to the investigation of IOP, in this study we explored the 24h behaviour of the
systolic and diastolic blood pressure and heart rate, and we found significant differences
between he two treatment periods.
In fact, systolic, diastolic blood pressure and heart rate values were found not different com-
pared to the untreated baseline values during bimatoprost 0.01% while they showed significant
changes during treatment with the timolol 0.5%. Specifically the systolic blood pressure was
found to be reduced at the night time-points (00:00 and 04:00) and at 3 out of 5 day timepoints
(12:00, 16:00, 20:00), while the diastolic blood pressure showed significant changes mainly dur-
ing the day with a significant dip at 08:00, 12:00 and 16:00 o’clock (Fig 3). Also the heart rate
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was found significantly reduced by timolol 0.5% at 5 out of 7 timepoints of the 24h curve with
mean nocturnal values reaching 60 bpm at 00:00 and 04:00. These findings are in agreement
with previous reports that showed significant changes in the cardiovascular parameters during
treatment with topical beta-blockers. Netland et al. showed in a randomized, double-masked
investigation of the 24h behaviour of cardiovascular parameters under topical treatment with
different beta-blockers that timolol causes a significant reduction in heart rate from midnight
to 04:00 o’clock and that 18.4% of patients became clinically significantly bradycardic (heart
rate<60 bpm) during topical timolol treatment [8].
Despite these findings confirm that the well known effects of beta blockers on blood pres-
sure and heart rate when administered systemically may be exerted also when they are admin-
istered topically in the form of eyedrops the clinical significance of the observed changes
remains to be ascertained. Hayreh et al. investigated the effect of topical beta-blocker eyedrops
on nocturnal arterial hypotension and heart rate and on visual field deterioration by prospec-
tively following 161 patients with glaucomatous optic neuropathy and they found that the use
of beta-blockers eyedrops is associated with nocturnal hypotension and reduced heart rate and
that these effects may be a potential risk factor for disease progression and visual field deterio-
ration in vulnerable individuals [7]. Nevertheless despite the pathogenetic mechanisms under-
lying this relationship have been not yet fully characterized Graham and Drance in their review
on the role of nocturnal hypotension in glaucoma concluded that there is enough evidence to
state that nocturnal hypotension may play a role in the progression of glaucomatous damage
probably via reduced perfusion of the optic nerve head [21].
In our study we calculated the mean 24h systolic and diastolic ocular perfusion pressure and
we found that while the diastolic was increased during bimatoprost 0.01% treatement (as the
result of a significant reduction of the IOP associated with no effects on blood pressure), the
systolic was found significantly reduced during timolol treatment (as the result of a lower effect
on the IOP associated with a reduction of the systolic blood pressure). Nevertheless it has to be
highlighted that ocular perfusion pressure is an arithmetically calculated vascular measure
whose clinical role is still under debate. Bonomi et al. in the Egna-Neumarkt Study found that
a lower diastolic perfusion pressure was associated with a marked, progressive increase in the
frequency of glaucoma [22]. More recently Caprioli et al., in their review about blood pressure,
perfusion pressure and glaucoma, concluded that low perfusion pressure and blood pressure
are associated with glaucoma despite there is still no evidence to support the value of correcting
low blood pressure as therapy for glaucoma mainly for the lack of crucial information about
the microvascular beds in which perfusion is important in glaucoma, and for the cardiovascular
safety concerns associated with treatments designed to increase ocular perfusion pressure and
blood flow by increasing blood pressure, especially in elderly patients [23]. In this context how-
ever, the results of the present study may help the clinician in personalizing the topical treat-
ment according to the individual patient’s glaucoma and cardiovascular characteristics.
Moreover the findings observed in our study of reduced blood pressure, heart rate and ocu-
lar perfusion pressure with timolol 0.5% administered twice daily associated with a good daily
effect on IOP but a weak effect on IOP during the night-time might suggest that timolol 0.5%
administered only once in the morning might have a similar 24h effect on IOP with reduced
impact on cardiovascular parameters. Nevertheless for a evidence-based once daily use of timo-
lol 0.5% future prospective specifically designed clinical trials are required.
Finally in the present trial both drugs under investigation showed a very good tolerability
profile with very low incidence of side effects. This finding is of particular interest considering
that patients were actively asked about the occurrence of specific side effects such as burning,
stinging, foreign body sensation or conjunctival hyperemia and despite the specific questions
the positive answers were very low for both timolol and bimatoprost 0.01%.
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One potential bias of crossover studies is the presence of potential carry-over effects of the
first treatment on the second treatment. We tested and excluded the presence of any carry-over
effect in the present study. The absence of carry-over effects is also supported by the finding of
similar mean 24h IOP in patients who received timolol 0.5% as first drug compared to patients
who received timolol 0.5% as a second drug (after bimatoprost). Similarly the mean 24h IOP
was not different in patients treated with bimatoprost 0.01% as a first drug compared to
patients treated with bimatoprost 0.01% as second drug. Additionally the mean 24h IOP was
statistically lower during bimatoprost 0.01% than during timolol 0.5% in both study arms so
either when bimatoprost 0.01% was used as first drug and when it was used as second drug in
the crossover design.
Among the limitations of the present trial it has to be highlighted that that the results refer
to the short term and might require confirmation in the long term and that only primary open
angle glaucoma patients and ocular hypertension subjects have been enrolled and that the
study results might not be generalisable to angle closure or secondary glaucomas. Moreover it
has to be highlighted that the present study was not designed to assess visual function out-
comes and no information can be directly derived about the relative effectiveness of the differ-
ent drugs in preventing the progression of visual field loss. Nevertheless large randomized
clinical trials, such as the EMGT and the CGS, have reported a significant reduction of the risk
of glaucoma progression (-11% to -19%) associated to each mmHg of IOP reduction obtained
by treatment, thus supporting the clinical relevance of differences of effectiveness between
drugs starting from 1 mmHg [2,4].
In conclusion, our results suggest that both bimatoprost 0.01% administered once at night
and timolol 0.5% administered twice daily are effective in reducing the mean 24h IOP with
timolol being less effective during the night hours. The observed effects of timolol on the sys-
tolic and diastolic blood pressure and heart rate might be clinically irrelevant in healthy indi-
viduals but should be considered in the process of choosing the right treatment for the
individual glaucoma and ocular hypertensive patient also considering the use of lower concen-
trations of the active drug.
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